1
|
Rauzier C, Chartrand DJ, Alméras N, Lemieux I, Larose E, Mathieu P, Pibarot P, Lamarche B, Rhéaume C, Poirier P, Després JP, Picard F. Plasma IGFBP-2 levels reveal heterogeneity in hepatic fat content in adults with excess visceral adiposity. Front Endocrinol (Lausanne) 2023; 14:1222101. [PMID: 37854178 PMCID: PMC10579942 DOI: 10.3389/fendo.2023.1222101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/13/2023] [Accepted: 09/05/2023] [Indexed: 10/20/2023] Open
Abstract
Lay summary Obesity is frequently accompanied by a fatty liver. However, some individuals with high abdominal fat levels nevertheless have low levels of liver fat. Reasons for such discordant phenotypes are unclear. In this paper, we report that among asymptomatic individuals with high levels of visceral fat, low concentrations of IGFBP-2 in the circulation were associated with significantly higher hepatic fat content compared to those with high IGFBP-2 levels. We conclude that quantification of plasma IGFBP-2 concentrations may be useful to identify the early risk for liver fat accumulation in apparently healthy individuals without cardiovascular symptoms. Aim/hypothesis Although excess visceral adiposity (VAT) is generally associated with increased liver fat (LF), recent evidence has revealed heterogeneity in LF content among adults with visceral obesity, potentially contributing to specific differences in cardiometabolic outcomes. Reasons for such discordant VAT-LF phenotypes are largely unknown. The present study aimed at assessing whether circulating levels of insulin growth-factor binding protein-2 (IGFBP-2) could be a useful biomarker in the identification of heterogenous and discordant VAT-LF phenotypes. Methods A sample of 308 middle-aged Caucasian apparently healthy men and women without cardiovascular symptoms were studied for the present cross-sectional analyses. Fasting plasma glucose and lipid levels were assessed and an oral glucose tolerance test was performed. Hepatic fat fraction (HFF) was measured using magnetic resonance spectroscopy whereas VAT was assessed by magnetic resonance imaging. Plasma IGFBP-2 levels were quantified by ELISA. Participants were then classified on the basis of median VAT (81 mL) and IGFBP-2 levels (233 ng/mL). Results Individuals with high levels of VAT were characterized by higher waist circumference, lower insulin sensitivity, as well as by higher plasma triglyceride and lower HDL-cholesterol levels. Plasma IGFBP-2 levels were inversely correlated with HFF (r = -0.39, p < 0.0001). Among men and women with high levels of VAT, those with low levels of IGFBP-2 had significantly higher HFF (7.5 ± 0.7%), compared to participants with high IGFBP-2 concentrations (3.2 ± 0.5%, p < 0.0001). Conclusion In the presence of excess VAT, high IGFBP-2 concentrations are associated with low levels of LF. Although additional studies will be necessary to establish causality and further clarify the clinical implications of these observations, these findings are concordant with a novel function of IGFBP-2 in modulating susceptibility to non-alcoholic fatty liver disease (NAFLD) in the presence of visceral obesity.
Collapse
Affiliation(s)
- Chloé Rauzier
- Centre de recherche de l’Institut universitaire de cardiologie et de pneumologie de Québec (IUCPQ) – Université Laval, Québec, QC, Canada
- Faculté de pharmacie, Université Laval, Québec, QC, Canada
| | - Dominic J. Chartrand
- Centre de recherche de l’Institut universitaire de cardiologie et de pneumologie de Québec (IUCPQ) – Université Laval, Québec, QC, Canada
- Département de kinésiologie, Faculté de médecine, Université Laval, Québec, QC, Canada
| | - Natalie Alméras
- Centre de recherche de l’Institut universitaire de cardiologie et de pneumologie de Québec (IUCPQ) – Université Laval, Québec, QC, Canada
- Département de kinésiologie, Faculté de médecine, Université Laval, Québec, QC, Canada
| | - Isabelle Lemieux
- Centre de recherche de l’Institut universitaire de cardiologie et de pneumologie de Québec (IUCPQ) – Université Laval, Québec, QC, Canada
| | - Eric Larose
- Centre de recherche de l’Institut universitaire de cardiologie et de pneumologie de Québec (IUCPQ) – Université Laval, Québec, QC, Canada
- Département de médecine, Faculté de médecine, Université Laval, Québec, QC, Canada
| | - Patrick Mathieu
- Centre de recherche de l’Institut universitaire de cardiologie et de pneumologie de Québec (IUCPQ) – Université Laval, Québec, QC, Canada
- Département de chirurgie, Faculté de médecine, Université Laval, Québec, QC, Canada
| | - Philippe Pibarot
- Centre de recherche de l’Institut universitaire de cardiologie et de pneumologie de Québec (IUCPQ) – Université Laval, Québec, QC, Canada
- Département de médecine, Faculté de médecine, Université Laval, Québec, QC, Canada
| | - Benoît Lamarche
- Centre Nutrition, santé et société (NUTRISS), Institut sur la nutrition et les aliments fonctionnels (INAF), Université Laval, Québec, QC, Canada
- École de nutrition, Faculté des sciences de l’agriculture et de l’alimentation, Université Laval, Québec, QC, Canada
| | - Caroline Rhéaume
- Centre de recherche de l’Institut universitaire de cardiologie et de pneumologie de Québec (IUCPQ) – Université Laval, Québec, QC, Canada
- Département de médecine familiale et de médecine d’urgence, Faculté de médecine, Université Laval, Québec, QC, Canada
- VITAM – Centre de recherche en santé durable, Québec, QC, Canada
| | - Paul Poirier
- Centre de recherche de l’Institut universitaire de cardiologie et de pneumologie de Québec (IUCPQ) – Université Laval, Québec, QC, Canada
- Faculté de pharmacie, Université Laval, Québec, QC, Canada
| | - Jean-Pierre Després
- Centre de recherche de l’Institut universitaire de cardiologie et de pneumologie de Québec (IUCPQ) – Université Laval, Québec, QC, Canada
- Département de kinésiologie, Faculté de médecine, Université Laval, Québec, QC, Canada
- VITAM – Centre de recherche en santé durable, Québec, QC, Canada
| | - Frédéric Picard
- Centre de recherche de l’Institut universitaire de cardiologie et de pneumologie de Québec (IUCPQ) – Université Laval, Québec, QC, Canada
- Faculté de pharmacie, Université Laval, Québec, QC, Canada
| |
Collapse
|
2
|
Cha DM, Woo SJ, Kim HJ, Lee C, Park KH. Comparative analysis of aqueous humor cytokine levels between patients with exudative age-related macular degeneration and normal controls. Invest Ophthalmol Vis Sci 2013; 54:7038-44. [PMID: 24106111 DOI: 10.1167/iovs.13-12730] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
PURPOSE To investigate the cytokine markers associated with exudative AMD present in aqueous humor. This goal was achieved by comparing the concentrations of more than 500 molecules in aqueous humor, between exudative AMD patients and controls. METHODS Aqueous humor samples were acquired from 20 patients with exudative AMD and 20 control subjects. Raybio human antibody array technology was used to simultaneously screen for any difference in the expression of any of 507 molecules. To validate the antibody array result, concentrations of insulin-like growth factor binding protein 2 (IGFBP-2), insulin-like growth factor-1 (IGF-1), and VEGF were measured by ELISA. RESULTS Twenty molecules studied exhibited intergroup differences. Twelve molecules including IGFBP-2, IGFBP-6, IGFBP-7, and glucocorticoid-induced tumor necrosis factor receptor family related gene (GITR) ligand, were detected in high densities in exudative AMD patients. Eight other molecules were present at higher concentrations in control patients. ELISA confirmed that IGFBP-2 levels were higher in patients with exudative AMD (7.47 ± 6.19 ng/mL) in comparison with control subjects (3.07 ± 3.34 ng/mL, P = 0.008). IGF-1 and VEGF levels were also increased in the former group (2.20 ± 0.26 vs. 1.99 ± 0.35 ng/mL, P = 0.040; 122.25 ± 63.24 vs. 86.98 ± 44.41 pg/mL, P = 0.048, respectively). CONCLUSIONS The pattern of cytokine expression in the aqueous humor of exudative AMD patients varies from that of normal control subjects. The increased levels of IGFBP-2 and IGF-1 in exudative AMD eyes indicate that the altered expression of IGF-related molecules may be involved in disease pathogenesis and suggests potential biomarkers for exudative AMD.
Collapse
Affiliation(s)
- Dong Min Cha
- Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea
| | | | | | | | | |
Collapse
|
3
|
Narayanan RP, Fu B, Oliver RL, Siddals KW, Donn R, Hudson JE, White A, Laing I, Ollier WER, Heald AH, Gibson JM. Insulin-like growth factor-II and insulin-like growth factor binding protein-2 prospectively predict longitudinal elevation of HDL-cholesterol in type 2 diabetes. Ann Clin Biochem 2013; 51:468-75. [PMID: 24081183 DOI: 10.1177/0004563213499145] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
INTRODUCTION Associations of insulin-like growth factor-II (IGF-II) and insulin-like growth factor binding protein-2 (IGFBP-2) with cardiovascular risk have been inadequately studied. We hypothesized that IGF-II and IGFBP-2 associate with longitudinal trends in lipid profiles in type 2 diabetes patients. SUBJECTS AND METHODS Four hundred and eighty nine subjects with type 2 diabetes (age 27-87 years) from the Salford Diabetes Cohort were studied. Longitudinal clinical information was extracted for an eight-year period (2002-2009) from an integrated electronic dataset of primary care and hospital data. RESULTS There were 294 male subjects and mean age was 62.9 years. At baseline, IGF-II concentration was 602 ng/mL. HDL cholesterol at baseline was associated with log-IGF-II concentration in a model adjusted for age, gender, baseline body-mass index (BMI), estimated glomerular filtration rate (eGFR) and lipid-lowering therapy. IGFBP-1 and IGFBP-2 were associated with high HDL-cholesterol. A higher circulating IGF-II concentration at baseline was also associated with longitudinal increase in HDL-cholesterol in mixed-effects regression analyses independent of IGF-I, IGFBP-1, IGFBP-2, IGFBP-3, age, gender, eGFR, BMI and lipid-lowering therapy. Log-transformed baseline concentrations of IGFBP-1 and IGFBP-2 were also associated with longitudinal elevation in HDL-cholesterol. No association was observed for IGF-II or IGFBP-2 with longitudinal LDL cholesterol trends. CONCLUSION Our analyses based on 'real world' data demonstrate that higher baseline IGF-II and IGFBP-2 predict increased HDL concentration over time, implicating IGF-II in modulation of circulating HDL-cholesterol concentrations.
Collapse
Affiliation(s)
- Ram P Narayanan
- Vascular Research Group, The University of Manchester, Manchester, UK
| | - Bo Fu
- School of Community Based Medicine, The University of Manchester, Manchester, UK
| | - Robert L Oliver
- Vascular Research Group, The University of Manchester, Manchester, UK
| | - Kirk W Siddals
- Vascular Research Group, The University of Manchester, Manchester, UK
| | - Rachelle Donn
- School of Community Based Medicine, The University of Manchester, Manchester, UK
| | - Julie E Hudson
- Vascular Research Group, The University of Manchester, Manchester, UK
| | - Anne White
- Endocrinology and Diabetes, Faculty of Medical, Human and Life Sciences, The University of Manchester, Manchester, UK
| | - Ian Laing
- Department of Biochemistry, Leighton Hospital, Crewe, UK
| | | | - Adrian H Heald
- Vascular Research Group, The University of Manchester, Manchester, UK Department of Medicine, Leighton Hospital, Crewe, UK
| | - J M Gibson
- Vascular Research Group, The University of Manchester, Manchester, UK
| |
Collapse
|
4
|
Catalioto RM, Valenti C, Liverani L, Giuliani S, Maggi CA. Characterization of a novel proinflammatory effect mediated by BK and the kinin B₂ receptor in human preadipocytes. Biochem Pharmacol 2013; 86:508-20. [PMID: 23796753 DOI: 10.1016/j.bcp.2013.06.005] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2013] [Revised: 06/05/2013] [Accepted: 06/06/2013] [Indexed: 12/16/2022]
Abstract
Obesity and adipose tissue contribute to local and systemic inflammation. However the role of the inflammatory mediator bradykinin (BK) in this context is not known. We therefore evaluated the effect of BK on adipokines secretion in human preadipocytes during the course of differentiation and characterized the receptors involved. Results obtained from antibody array and ELISA experiments showed that several adipokines are released by human preadipocytes under basal conditions while BK specifically stimulated the production of interleukin(IL)-6 and IL-8. The effect of BK diminished with the progression of differentiation, being almost inactive on adipocytes. In preadipocytes, BK also induced a rapid and transient [Ca²⁺](i) mobilization, a rapid and sustained increase in ERK1/2 activation and enhanced forskolin-stimulated cAMP accumulation. BK was without effect on cell proliferation and viability as assessed by bromodeoxyuridine incorporation, WST-1 conversion, or lactate dehydrogenase leakage and was without effect on adipogenesis as measured by triglyceride accumulation, GPDH activity and leptin release. The B₁ receptor agonist, Lys-[des-Arg⁹]-BK, displayed poor activity or was without effect while overall BK effects were prevented by the selective B₂ receptor antagonist, fasitibant chloride, but not by the B₁ selective antagonist, Lys-[Leu⁸][des-Arg⁹]-BK. Immunoblot analysis and immunofluorescence studies showed that the kinin B₂ receptor was essentially expressed at the beginning of the differentiation program. In conclusion, human preadipocytes expressed kinin B₂ receptors linked to multiple signaling pathways, IL-6 and IL-8 production, and BK proinflammatory response in adipose tissue could be prevented by fasitibant chloride.
Collapse
Affiliation(s)
- Rose-Marie Catalioto
- Pharmacology Department, Menarini Ricerche SpA, Via Rismondo 12A, 50131 Florence, Italy.
| | | | | | | | | |
Collapse
|